Clinical Trials Browser

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, Mantle-Cell

NCT00555048 2017-05-24

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 1/2 Terminated

1 enrolled 5 charts

LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Erythroblastic, Acute, Graft vs Host Disease, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT00058825 2016-11-07

HIMSUM

Phase 1/2 Terminated

27 enrolled 13 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Phase 1/2 Terminated

4 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00077961 2015-03-26

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Phase 1/2 Terminated

49 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT00051701 2015-03-05

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

61 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

HIMSUM

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma